39 results about "Booster immunizations" patented technology

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and / or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime / boost vaccination strategy.

The invention provides a method for purifying foot-and-mouth disease based on a method for detecting suspected positive foot-and-mouth disease virus nucleic acid, and aims to thoroughly remove foot-and-mouth disease pathogens in a group and in the environment. According to the provided method, an ELISA kit is used for detection, the kit comprises a monoclonal antibody, the amino acid sequence of a heavy chain of the monoclonal antibody is SEQ ID NO: 7, and the amino acid sequence of a light chain of the monoclonal antibody is SEQ ID NO: 9. The method comprises the following steps: enhancing immunization of pigs with unqualified antibodies, detecting foot-and-mouth disease neutralizing antibodies and VP1 antibodies after immunization, and eliminating immune antibody negative and VP1 antibody positive pigs. The ELISA kit provided by the invention is strong in stability and good in sensitivity, and when the kit is used for checking in a large-scale pig farm, the purification of the foot-and-mouth disease can be effectively realized. The purification method provided by the invention is high in accuracy and easy to popularize and apply.

The application belongs to the field of marine biotechnology, and specifically discloses a preparation method of a long oyster insulin-like peptide receptor (ILPR) polyclonal antibody and application thereof. The method is characterized by the following steps: specific antigen epitopes of the long oyster ILPR protein are screened through bioinformatics analysis, a pET32a-ILPR recombinant plasmid is constructed and induced to express in Escherichia coli; the purified recombinant protein is used as an immunogen to immunize New Zealand white rabbits, and rabbit antisera are collected after four times of booster immunization; specific polyclonal antibodies are purified by using antigen affinity chromatography technology, and can specifically recognize the ILPR protein in long oyster tissues. The antibody prepared by the application has high specificity and sensitivity, and provides an important biological tool for studying the insulin signal transduction pathway, growth regulation and energy metabolism mechanism of long oysters.

The present invention relates i.a. to a method for treating or preventing avian influenza virus infections in avians comprising a first administration of an effective amount of a rHVT-H5HA COBRA and a second administration of an effective amount of an inactivated H5 vaccine or H5HA protein.

The invention relates to the field of animal models, and discloses an anti-NMDAR encephalitis animal model induced by combination of GluN1 polypeptide active immunization and sleep deprivation as well as an establishment method and application thereof, and the establishment method of the anti-NMDAR encephalitis animal model induced by combination of GluN1 polypeptide active immunization and sleep deprivation comprises the following steps: 1) immunizing an animal with synthesized GluN1359-378 polypeptide according to a primary immunization-enhancement strategy; (2) in the second week after the boosted immunization, sleep deprivation operation is carried out on the animals for 12 hours every day, and the operation lasts for 3 weeks; by adopting the establishment method, the anti-NMDAR encephalitis animal model induced by GluN1 polypeptide active immunization and sleep deprivation can be established; the GluN1 polypeptide active immunization combined sleep deprivation induced anti-NMDAR encephalitis animal model can be applied to research on the morbidity process and mechanism of sleep disorder induced anti-NMDAR encephalitis, research on the morbidity process and mechanism of anti-NMDAR encephalitis, and screening and evaluation of anti-NMDAR encephalitis prevention and treatment drugs.

The invention relates to the technical field of biological medicines, and particularly discloses an egg yolk antibody for resisting canine interleukin as well as a preparation method and application of the egg yolk antibody. The egg yolk antibody is prepared by taking immunocompetence antigen epitope peptide of canine interleukin-31 as an immunogen, the antigen epitope peptide is obtained by predicting key antigen epitopes of IL-31 through an Antigenic tool and performing series optimization, a coding gene of the antigen epitope peptide is optimized by an escherichia coli codon to construct a recombinant expression vector, and high-purity antigen is obtained by inducible expression and purification. A laying hen is immunized by the antigen, after basic immunization and two times of booster immunization, the egg yolk antibody is extracted from egg yolk and purified to obtain the egg yolk antibody, and the ELISA of the egg yolk antibody is obviously superior to that of an antibody prepared by commercial canine IL-31 protein immunization. The egg yolk antibody can be specifically combined with canine IL-31, the histamine level in serum of a canine with pruritus is remarkably reduced, the atopic dermatitis related pruritus symptoms are effectively relieved, an efficient and safe biological treatment preparation is provided for canine IL-31 mediated pruritus diseases, and the egg yolk antibody has wide clinical application prospects.

The invention provides an application of a fusion protein in preparation of an SARS-CoV-2 broad-spectrum vaccine, the fusion protein comprises an NTD structural domain and an RBD structural domain of an SARS-CoV-2 spike protein, provides more conservative epitopes, can effectively stimulate the generation of a neutralizing antibody, and can effectively inhibit the generation of the SARS-CoV-2 spike protein. The vaccine prepared by using the fusion protein can provide broad-spectrum and efficient protection for the SARS-CoV-2 wild type and various mutant strains; the invention also provides an application of the broad-spectrum vaccine as an immune enhancer, and also provides an immune kit under a corresponding immune strategy, the broad-spectrum vaccine can cooperate with other existing vaccines to enhance immunity, and can independently perform a complete immune procedure, and excellent immune protection can be provided in any way.

The invention relates to the technical field of medicine, in particular to an antigen double burst release self-boosting immune vaccine and application thereof.The antigen double burst release self-boosting immune vaccine is characterized in that antigens are loaded inside and outside complex coacervation microcapsules in the vaccine, nanoparticles are prepared through a nanoprecipitation method, the nanoparticles and cell membranes jointly entrap the antigens to form functional nanoparticles, and the functional nanoparticles are used as functional nanoparticles; the preparation method comprises the following steps: coating functionalized nanoparticles by using a micro-fluidic technology and a complex coagulation method to prepare microcapsules, coating the surface of the microcapsules by using dopamine hydrochloride auto-polymerization reaction to form coating microcapsules, and finally blending with the functionalized nanoparticles, thereby dividing the antigen into an inner part and an outer part. After entering a body, the nano-microparticle carrier double burst release vaccine is subjected to antigen double burst release with time lag intervals in different time periods; the prepared vaccine can release antigens firstly, then effectively collect and activate antigen presenting cells, the antigen presenting cells uptake the antigen presenting cells to cause immune response, and the generation of specific antibodies can be effectively induced by two times of antigen release through the time-delay coating, so that a traditional natural immune procedure is simulated.

Abstract The present disclosure provides a method for vaccinating a subject against a mucosal virus 5 infection, comprising administering to the subject an immunologically effective amount of an intranasal booster, wherein the intranasal booster comprises detoxified Escherichia coli labile toxin (LT) and an antigen from the mucosal virus, and wherein the subject has been previously primed. An intranasal vaccine composition comprising an immunologically effective amount of a mucosal virus antigen adjuvanted with a detoxified Escherichia coli labile toxin (LT) is also .0 provided. ~22~ Sep 2023 Abstract 5 2023237105 27 ~22~

The invention relates to the technical fields of monoclonal antibody preparation, adjuvants, animal immunization and the like, and discloses an application of Mn adjuvant in rapid immunization in humanized mice, which comprises the following steps: (1) mixing immunogen and Freund's complete adjuvant according to a volume ratio of 1: 1, and emulsifying to obtain a primary immunizing agent; (2) mixing an immunogen and a Mn adjuvant according to a volume ratio of 1: 1 to obtain an immunizing agent; and (3) collecting serum S0 3 days before primary immunization of the humanized mouse, collecting serum S1 on the 21st day after immunization, and carrying out serum titer detection on the serum S0 and the serum S1 so as to determine the specific antibody titer (concentration) in the serum. According to the invention, the Mn adjuvant is applied to the humanized mouse for the first time, the Mn adjuvant is also applied to the rapid immunization technology for the first time, and meanwhile, the rapid immunization technology is also applied to the humanized mouse for the first time, so that not only is a good effect achieved, but also time and cost are effectively reduced.

The invention discloses a method for preparing a high-titer polyclonal antibody from a Zika virus strain, which comprises the following steps: selecting the Zika virus strain, culturing in cells, and purifying virus particles with high purity to prepare an immunogen; an optimized animal immunization strategy is adopted and comprises the steps of selecting a proper host animal, applying a potent immunologic adjuvant, namely a Freund's adjuvant, and designing a scientific immunization program, so that humoral immune response of the host is stimulated to the maximum extent; when the titer of the antibody reaches a peak value, collecting antiserum, synthesizing hybridoma cells through splenocytes, and obtaining the high-purity polyclonal antibody through a multi-step purification technology. According to the method, high-purity and non-chemically-inactivated whole virus particles which retain natural conformation are used as immunogens, a mode of primary immunization and multiple booster immunization is adopted, a Freund's adjuvant is combined, animals are continuously stimulated to generate high-titer antibodies, non-specific antibodies and impurities are effectively removed through multi-step purification, and the immunogen immunogen is obtained. The target antibody with high purity and high specificity is obtained.

The present invention provides compositions, vaccines, and methods for inducing protective immunity to immunogens in humans. Protective immune responses are obtained by using saRNA, particularly VRP vectors as a prime and MVA vectors for boosting. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors that contain at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus (e.g., EBV).

This invention provides a monoclonal antibody against the VP2 protein of a mandarin fish two-segmented RNA virus, its preparation method, and its application. The VP2 protein was obtained by expression and purification using recombinant plasmids. Mice were immunized three times, and mice with the highest serum titer were selected for intraperitoneal booster immunization against VP2 protein. Mouse spleen cells and SP2 / 0 myeloma cells were fused, and hybridoma cell lines secreting VP2 protein antibodies were screened. These cells were then subcloned to obtain four stable hybridoma cell lines secreting anti-VP2 protein antibodies, and their heavy and light chain variable region sequences were determined. Mice were injected intraperitoneally with Freund's incomplete adjuvant, followed by the injection of the hybridoma cell lines. Ascites fluid was collected from the mice, extracted, purified, and used to obtain the monoclonal antibody against the VP2 protein. Using these four monoclonal antibodies, three highly conserved and specific antigenic epitopes of the VP2 protein of the mandarin fish two-segmented RNA virus were screened and identified. This invention provides support for establishing specific serological methods for mandarin fish two-segmented RNA viruses and for further research on the biological function and clinical diagnosis of VP2.

The present application relates to a kind of anti-recombination canine interleukin-1β yolk antibody and its preparation method and application, the preparation method utilizes genetic engineering prokaryotic expression preparation antigen recombination canine interleukin-1β, antigen recombination canine interleukin-1β is emulsified after first immunization egg chicken with first immunoadjuvant, again the recombination canine interleukin-1β antigen is emulsified to egg chicken with second immunoadjuvant, and egg chicken is strengthened immunization, collect egg, separate egg yolk and extract the antibody in the yolk of egg, successfully obtain anti-recombination canine interleukin-1β yolk antibody, the titer of the yolk antibody is 1:409600, and higher purity, with better specificity and stability, can provide stable antigen and antibody material basis for canine IL-1β related detection, antibody preparation and subsequent application research, with wide application prospect.

The present invention discloses a vaccine of wetland virus glycoprotein Gc and its application, which belongs to the field of biomedical technology. The wetland virus glycoprotein Gc is a recombinant wetland virus glycoprotein Gc, and the wetland virus glycoprotein Gc is a truncated glycoprotein truncated at the C-terminus; the amino acid sequence of the truncated wetland virus glycoprotein Gc is the protein shown in positions 1-525 of SEQ ID No. 1. After immunizing mice with the vaccine of the present invention, high-titer antibodies against the truncated wetland virus glycoprotein Gc can be produced, and the authentic WELV virus can be neutralized; after boosting immunization of mice with the vaccine prepared by the present invention, 100% of the mice can be protected from death threat under the fully lethal dose of WELV; the recombinant truncated WELV glycoprotein Gc subunit candidate vaccine prepared by the present invention has good safety, can effectively stimulate the immune response, and can completely protect mice from death threat.

An aspect provides a vaccine composition for preventing tuberculosis comprising chorismate mutase. The vaccine composition alone may induce immunity specific to Mycobacterium tuberculosis, and when provided together with an immune adjuvant, the vaccine composition may induce immunity specific to tuberculosis more effectively. Furthermore, when an existing vaccine for tuberculosis is used as a prime and the vaccine composition according to an aspect including chorismite mutase is provided as a booster, the immunity specific to tuberculosis may be induced significantly more effectively.

The invention is applicable to the technical field of biology, and provides a streptococcus suis type 2 multi-epitope inhalation type subunit vaccine and application thereof. According to the invention, 4 CTL epitopes, 7 HTL epitopes and 6 B cell epitopes are screened out aiming at conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, the epitopes are fused by AAY / GPGPG / EAAAK linkers, L7 / L12 ribosomal protein is introduced as an adjuvant, and the inhalation type subunit vaccine 1022-SpaA V3 is constructed; the vaccine can improve the levels of sIgA and serum IgG of respiratory mucosa and activate related immune cells by virtue of 60 micrograms of intranasal primary immunization-enhanced immunization, so that a mucosa and system dual immune mechanism is formed; the survival rate of mice after SS2 multi-strain challenge reaches up to 100%, and the bacterial load can be reduced; and the vaccine is safe and non-toxic, is inhaled, saves cost and is suitable for industrial large-scale production.

The invention provides a PDCoV non-structural protein Nsp2 polyclonal antibody and a preparation method and application thereof, and the method comprises the following steps: diluting purified recombinant Nsp2 protein with PBS to obtain a diluent; emulsifying the diluent and a freund's complete adjuvant according to a volume ratio of (0.5-1.5): 1 to obtain an emulsion; performing immunization on the rabbits according to the emulsion, wherein the immunization mode is subcutaneous injection; the emulsion is adopted for enhancing immunization of the rabbits twice every 10-18 days; and carrying out heart blood collection on the rabbit on the 7th-8th day after the two times of boosted immunization to obtain the polyclonal antibody. The polyclonal antibody prepared by the embodiment of the invention can specifically recognize the Nsp2 protein, and can be used for Nsp2 protein detection, protein function identification, cell sub-localization and the like.

The invention relates to the technical field of preparation of tuberculosis vaccines, in particular to preparation and application of a VLP vaccine APEH + mi3 + AS01E for enhancing BCG immunity. The preparation method comprises the following steps: mixing Ag85B-mi3, PPE33-mi3, ESAT-6-mi3 and HSPX-mi3 to obtain multivalent nanoparticles, and fully emulsifying the multivalent nanoparticles and an AS01E adjuvant to obtain the VLP vaccine APEH + mi3 + AS01E. After the VLP vaccine APEH + mi3 + AS01E provided by the invention is immunized, strong Th1 type, Th2 type and Th17 type cellular immune responses are induced; after H37Rv challenge, the immune response of Th1 type, Th2 type and Th17 type cells induced by the multivalent mi3VLP vaccine is stronger than that of BCG, and the Mtb H37Rv infection resistance is slightly higher than that of BCG; the vaccine is used as a BCG reinforcing vaccine, and can effectively reinforce the short-term protective immune response of the BCG and the anti-tubercle bacillus protection effect.

The present invention relates to an intestinal microorganism-based composition for enhancing the efficacy of vaccinations, in particular, the persistence of antibody reactions and booster effects. The present inventors have found that specific intestinal microorganisms are significantly abundant in individuals having a long antibody half-life following vaccination with an mRNA vaccine or an adenovirus vector vaccine, or exhibiting a high immune response upon booster vaccination. Specifically, it was found that a specific microbial community including Faecalibacterium prausnitzii is associated with antibody persistence and booster response enhancement following mRNA vaccination, and Escherichia coli is associated with antibody persistence following adenovirus vector vaccination.

The invention relates to combinations for treating or preventing cancer comprising a closed linear DNA molecule and an mRNA molecule. The invention also relates to a closed linear DNA molecule and an mRNA molecule for use in a heterologous prime-boost immunization regimen in a subject. In addition, the invention relates to methods and kits incorporating and / or using the closed linear DNA molecule and the mRNA molecule.

The invention discloses a composite adjuvant composition and application, and belongs to the technical field of vaccines. The composite adjuvant composition comprises the neutral liposome, the CpG adjuvant and the QS-21, and through the synergistic effect of all the components, the defects that a traditional adjuvant is single in immune response, insufficient in antigen presentation efficiency and the like are effectively overcome. When being applied to a vaccine containing the norovirus-like particles, the norovirus-like particles can efficiently induce humoral immunity (IgG and subtype) and cellular immunity (memory T cells) at the same time, reduce the frequency of boosting immunity, are good in safety, and provide an efficient technical scheme for research and development of antiviral vaccines.

The invention relates to the technical field of veterinary biological products, in particular to a preparation method of a mixed vaccine for combined immunization of foot-and-mouth disease and other pig live vaccines and an immunization method. The preparation method of the mixed vaccine for combined immunization of the foot-and-mouth disease and other pig live vaccines comprises the following steps: heating the foot-and-mouth disease inactivated vaccine to 20-25 DEG C, using the foot-and-mouth disease inactivated vaccine as a dilution matrix, dissolving the pig live vaccines needing combined immunization, and uniformly mixing to form a stable emulsion, thereby obtaining the mixed vaccine. According to the mixed vaccine disclosed by the invention, the immunological injection times are reduced, and the stress and cross infection risks of pigs are reduced; it is ensured that the titer of antibodies corresponding to all vaccines after combined immunization reaches the protection standard, and the immunization effect is better than that of independent immunization or simple mixed immunization; the method is simple to operate, low in cost and suitable for popularization and application in the aspect of enhancing immunity in large-scale pig farms.

The invention discloses a construction method and application of an anti-NMDAR encephalitis disease animal model. The construction method comprises the following steps: mixing a GluN1 (359-378) peptide fragment and mycobacterium tuberculosis (Mtb) into an incomplete Freund adjuvant to obtain an emulsified mixture, performing subcutaneous injection to two sides of the back of an anesthetized mouse, and performing intraperitoneal injection of a pertussis toxin (PTX) solution; injecting the PTX solution with the same concentration into the abdominal cavity of the mouse after 48 hours; after 14 days, repeating the first operation to carry out secondary boosted immunization on the mouse; injecting the PTX solution into the abdominal cavity again after 16 days; and after 32-35 days, biological detection is carried out to determine that modeling succeeds. According to the construction method, the period is greatly shortened, and the experiment efficiency is improved; according to the method, through an optimized immune scheme, the model success rate is high, and the phenotype is stable; the model is an active immune model and can simulate a complete disease process from autoantibody generation and immune cell infiltration to central nervous system injury.

The present invention provides compositions, vaccines and methods for inducing protective immunity against an immunogen in humans. The protective immune response is obtained by using a saRNA, in particular a VRP vector as prime and a MVA for boost. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus such as EBV.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody for HPV16 type E7 protein detection and application of the monoclonal antibody. E7 protein serving as an antigen and a Freund's complete adjuvant are mixed, then a mouse is subjected to primary immunization, then the E7 protein and a Freund's incomplete adjuvant are mixed, then the mouse is subjected to enhanced immunization, and the HPV16 type E7 protein detection monoclonal antibody is obtained. The monoclonal antibody for detecting the HPV16 type E7 protein is prepared by taking mouse splenocytes and myeloma cells to be fused to prepare hybridoma cells, then performing clone detection on the hybridoma cells to screen the hybridoma cells aiming at the specificity of the HPV16 type E7 protein, and finally obtaining the monoclonal antibody for detecting the HPV16 type E7 protein. According to the present invention, the HPV16 type E7 antigen detection kit is developed by using the immunochromatography method, and the kit has advantages of high sensitivity, strong specificity, simple operation and fast detection speed, and can be used for rapid screening diagnosis and illness state monitoring of HPV16.

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and / or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime / boost vaccination strategy.

The application belongs to the technical field of biotechnology, and provides a Streptococcus suis type 2 (SS2) multi-epitope inhalation subunit vaccine and application thereof.Four CTL epitopes, seven HTL epitopes and six B cell epitopes are screened from the conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, and the four CTL epitopes, the seven HTL epitopes and the six B cell epitopes are fused by AAY / GPGPG / EAAAK linkers and introduced into L7 / L12 ribosomal protein as an adjuvant to construct an inhalation subunit vaccine 1022-SpaA V3.The vaccine is intranasally primed and boosted at 60 μg, can improve respiratory mucosa sIgA and serum IgG levels, activate related immune cells, and form a mucosal and systemic double immune mechanism.The survival rate of mice after SS2 multi-strain challenge is up to 100%, and the bacterial load can be reduced.The vaccine is safe and non-toxic, inhalation can save cost, and is suitable for industrial scale production.

Sequential immunization strategies to guide the maturation of antibodies against the human immunodeficiency virus (HIV) are described. The sequential immunization strategies utilize an HIV envelope protein (Env) that binds germline (gl) B cells as a first (prime) immunization and an Env with a functional glycosylated N276 as a second (boost) immunization. The sequential immunization strategies successfully elicit neutralizing antibodies against HIV.

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and / or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime / boost vaccincation strategy.